Bevacizumab for newly diagnosed glioblastoma

New England Journal of Medicine

Volumn 370, Issue 21, 2014, Pages 2048-2049

  Haines, Ian E ^a   Gabor Miklos, George L ^b  

^a MONASH UNIVERSITY   (Australia)

^b Atomic Oncology   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY;

CANCER SURVIVAL; CLINICAL EFFECTIVENESS; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; GLIOBLASTOMA; HUMAN; LETTER; OVERALL SURVIVAL; PRIORITY JOURNAL; QUALITY OF LIFE; UNSPECIFIED SIDE EFFECT; BRAIN TUMOR; NOTE; BRAIN CANCER; COGNITION; DATA COLLECTION METHOD; EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER QUALITY OF LIFE QUESTIONNAIRE; LONGITUDINAL STUDY; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL (TOPIC); QUESTIONNAIRE; RISK BENEFIT ANALYSIS; TUMOR GROWTH;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; BRAIN NEOPLASMS; GLIOBLASTOMA; HUMANS;

EID: 84901026740     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1403303     Document Type: Letter

References (5)

1. Gilbert MR, Dignam JJ, Armstrong TS, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 2014;370:699-708.
2. Chinot OL, Wick W, Mason W, et al. Bevacizumab plus radiotherapy- temozolomide for newly diagnosed glioblastoma. N Engl J Med 2014;370:709-22.
3. Drazen JM. Open data. N Engl J Med 2014;370:662.
4. Fine HA. Bevacizumab in glioblastoma - still much to learn. N Engl J Med 2014;370:764-5.
5. Ross JS, Krumholz HM. Ushering in a new era of open science through data sharing: the wall must come down. JAMA 2013;309:1355-6.